Cell substratum interactions play an important role in adhesion, migration, growth, and differentiation of cells. These interactions are frequently altered in malignant cells. This proposal focuses on the molecular characterization of the cell-matrix interactions and their participation in physiologic and pathologic phenomena. We have found that the cell attachment site in fibronectin, vitronectin, fibrinogen, and apparently also in von Willebrand factor is an arginine-glycine-aspartic acid tripeptide. We have also isolated cell surface receptors which specifically recognize Arg-Gly-Asp sequences in these proteins. Continuing studies on the Arg-Gly-Asp recognition system will aim at a complete molecular description of the receptor-Arg-Gly-Asp interactions and the elucidation of the role of these and other related cell surface recognition systems in cell adhesion, growth and differentiation in vitro, and cell migration, tissue localization and tumorigenicity in vivo. The structure and biological roles of proteoglycans is being examined using molecular cloning of their core proteins. Proteoglycan core protein cDNAs already cloned or to be cloned will be used to derive sequence information on the core proteins. The cDNAs and the corresponding genes will also be used to express proteoglycans or to suppress the existing expression of proteoglycans in tissues and cultured cells. Results of this work will allow determination of the effects of proteoglycan expression on cellular properties such as cell adhesion and invasiveness of tumor cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Unknown (R35)
Project #
5R35CA042507-06
Application #
3479327
Study Section
Special Emphasis Panel (SRC)
Project Start
1986-07-01
Project End
1993-06-30
Budget Start
1991-07-01
Budget End
1992-06-30
Support Year
6
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Sanford-Burnham Medical Research Institute
Department
Type
DUNS #
009214214
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Orend, G; Hunter, T; Ruoslahti, E (1998) Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells. Oncogene 16:2575-83
Kolset, S O; Mann, D M; Uhlin-Hansen, L et al. (1996) Serglycin-binding proteins in activated macrophages and platelets. J Leukoc Biol 59:545-54
Narita, I; Border, W A; Ketteler, M et al. (1995) L-arginine may mediate the therapeutic effects of low protein diets. Proc Natl Acad Sci U S A 92:4552-6
Rasmussen, L M; Wolf, Y G; Ruoslahti, E (1995) Vascular smooth muscle cells from injured rat aortas display elevated matrix production associated with transforming growth factor-beta activity. Am J Pathol 147:1041-8
Koivunen, E; Wang, B; Ruoslahti, E (1995) Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology (N Y) 13:265-70
Aspberg, A; Binkert, C; Ruoslahti, E (1995) The versican C-type lectin domain recognizes the adhesion protein tenascin-R. Proc Natl Acad Sci U S A 92:10590-4
Hildebrand, A; Romaris, M; Rasmussen, L M et al. (1994) Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem J 302 ( Pt 2):527-34
Vuori, K; Ruoslahti, E (1994) Association of insulin receptor substrate-1 with integrins. Science 266:1576-8
Ruoslahti, E; Noble, N A; Kagami, S et al. (1994) Integrins. Kidney Int Suppl 44:S17-22
Wolf, Y G; Rasmussen, L M; Ruoslahti, E (1994) Antibodies against transforming growth factor-beta 1 suppress intimal hyperplasia in a rat model. J Clin Invest 93:1172-8

Showing the most recent 10 out of 69 publications